Jaemoon Lee

This inventor holds 9 USPTO granted patents, plus 1 CIPO patent and 4 EPO patents. Top assignee: Eisai R&d Management Co., Ltd.. Active years: 2016-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jaemoon Lee. Retrieved from https://idiyas.com/inventor/jaemoon-lee-jx0u6spw

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9

% Patents Active = 100.0

CIPO Patents = 1

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 6.6

ph-index = 4

Forward Citations = 39(Granted Patents)

Company Filing History:

9 out of 530

Eisai R&d Management Co., Ltd.

patents

Years Active: 2016-2023

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11643418 - Macrocyclization reactions and intermediates and other fragments useful in the synthesis of analogs of halichondrin B (2023-05-09),

2. 11434246 - EP4 antagonists (2022-09-06),

3. 10941148 - EP4 antagonists (2021-03-09),

4. 10934307 - Macrocyclization reactions and intermediates and other fragments useful in the synthesis of analogs of halichondrin B (2021-03-02),

5. 10611773 - Macrocyclization reactions and intermediates and other fragments useful in the synthesis of analogs of halichondrin B (2020-04-07),

6. 10316040 - EP4 antagonists (2019-06-11),

7. 10221189 - Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin B (2019-03-05),

8. 9783549 - Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin B (2017-10-10),

9. 9416109 - Methods and compounds useful in the synthesis of orexin-2 receptor antagonists (2016-08-16),

Title: The Innovative Contributions of Jaemoon Lee

Introduction

Jaemoon Lee is a prominent inventor based in Andover, MA, known for his significant contributions to the field of pharmaceutical chemistry. With a total of nine patents to his name, he has made remarkable advancements in drug synthesis and development.

Latest Patents

Among his latest patents, Lee has developed methods for macrocyclization reactions and intermediates that are useful in synthesizing analogs of halichondrin B. This invention provides a strategy for synthesizing eribulin or its pharmaceutically acceptable salts, such as eribulin mesylate. The macrocyclization strategy involves subjecting a non-macrocyclic intermediate to various carbon-carbon bond-forming reactions, including olefination reactions and catalytic ring-closing olefin metathesis. Additionally, he has worked on EP4 antagonists, providing compounds and formulations for cancer treatment.

Career Highlights

Jaemoon Lee is currently employed at Eisai R&D Management Co., Ltd., where he continues to innovate in the pharmaceutical sector. His work focuses on developing new therapeutic agents that can significantly impact patient care.

Collaborations

Lee has collaborated with notable colleagues, including Hyeong-wook Choi and Francis Gerard Fang, to further enhance the scope and impact of his research.

Conclusion

Jaemoon Lee's contributions to pharmaceutical chemistry through his innovative patents and collaborative efforts highlight his role as a leading inventor in the field. His work continues to pave the way for advancements in cancer treatment and drug synthesis.

Profile summary based on public USPTO records.